Q-omics provides the consensus-scored CDH26 profile across patient tissues and cancer cell-line models. CDH26 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CDH26 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CDH26 RNA expression shows 16,880 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KIRC, and UVM as cancer lineages where CDH26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDH26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDH26 survival associations across molecular data types. CDH26 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (11) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDH26 RNA expression–survival associations across cancer types. High CDH26 expression shows unfavorable associations in KIRP, LGG and KICH, but favorable associations in LUAD, HNSC and PAAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CDH26 RNA expression.
This table summarizes CDH26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CDH26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDH26 shows lower tumor expression in HNSC, LUAD and KICH and higher tumor expression in KIRC, BLCA and LIHC. The KIRC box plot shows higher CDH26 RNA expression in tumor versus normal tissue (log2 FC = +0.285, t-test p < 0.001).
This table shows molecular features associated with CDH26 in patient tissues and cancer cell lines. In patient samples, CDH26 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CDH26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
